All In Biotech

Drug Trial Radar · NCT02410772

TBTC Study 31: Rifapentine-containing Tuberculosis Treatment Shortening Regimens

Rifapentine-containing Treatment Shortening Regimens for Pulmonary Tuberculosis: A Randomized, Open-label, Controlled Phase 3 Clinical Trial. TBTC Study 31, ACTG Study A5349

Last checked: Nov 20, 2026Latest source record: Dec 4, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 2,516 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,516

Actual

Start

Jan 25, 2016

Primary completion

Jul 2020

Study completion May 2021

Sponsor

Sponsor type
Federal agency
Collaborators
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
First posted
Apr 8, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether one or two four-month regimens of tuberculosis treatment are as effective as a standard six-month regimen for treatment of pulmonary tuberculosis (TB). All three regimens are administered daily, seven days each week, with direct observation of each dose by a health-care worker at least five of the seven days of each week. The standard six-month regimen is two months of isoniazid, rifampin, ethambutol, and pyrazinamide followed by four months of isoniazid and rifampin. The first short regimen is a single substitution of rifapentine for rifampin: two months of isoniazid, rifapentine, ethambutol, and pyrazinamide, followed by two months of isoniazid and rifapentine. The second short regimen is a double substitution of rifapentine for rifampin and moxifloxacin for ethambutol: two months of isoniazid, rifapentine, moxifloxacin, and pyrazinamide, followed by two months of isoniazid, rifapentine, and moxifloxacin. Target enrollment is 2500 participants. Each study participant will remain in the study for 18 months in order to include at least 12 months of evaluation of whether the participant's TB recurs.

Conditions

  • Tuberculosis

Interventions

  • rifapentineDrug

    Regimen 2: Rifapentine is substituted for rifampin as the basis of 4-month treatment

  • rifapentine and moxifloxacinDrug

    Regimen 3: In addition to the single substitution described for regimen 2, a second substitution is added, of moxifloxacin for ethambutol.

  • controlDrug

    standard six-month treatment

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. TB Disease-free Survival at 12M After Study Treatment Assignment Among Participants in Control Regimen, Regimen1 (2HRZE/4HR) to Experimental Regimens, Regimen3 (2HPZM/2HPM) and Regimen2 (2HPZ/2HP) (Modified Intent to Treat [MITT] Population)Time frame: Twelve months after treatment assignment
  2. TB Disease-free Survival at 12M After Study Treatment Assignment Among Participants in Control Regimen, Regimen1 (2HRZE/4HR) to Experimental Regimens, Regimen3 (2HPZM/2HPM) and Regimen2 (2HPZ/2HP) (Assessable Population)Time frame: Twelve months after treatment assignment
  3. Percentage Participants With Grade 3 or Higher Adverse Events During Study Drug Treatment in Control Regimen (Regimen 1 2HRZE/4HR) Compared to Experimental Regimens, Regimen 3 (2HPZM/2HPM) and Regimen 2 (2HPZ/2HP) (Safety Analysis Population)Time frame: Four months and up to 14 days after last does of after study treatment (Regimen 2 and 3) or Six months and up to 14 days after last does of after study treatment (Regimen 1)

Locations

33 sites in 13 countries. Site status is shown where the registry gives one.

  • TBTC Site 82/ ACTG Site 801 USCF AIDS CRS

    San Francisco, California

  • TBTC Site 24 Columbia Unversity

    New York, New York

  • TBTC Site 20 UNTHSC (University of North Texas Health Science Center)

    Fort Worth, Texas

  • TBTC Site 62 Baylor College of Medicine & Affiliated Hospitals/VA

    Houston, Texas

  • TBTC Site 63 San Antonio VA Medical Center (South Texas Group)

    San Antonio, Texas

  • TBTC Site 91/ ACTG Site 12101 Insituto Nacional de Pesquisa Clínica Evandro Chagas

    Rio de Janeiro, Brazil

  • TBTC Site 94/ ACTG Site 12201 Hospital Nossa Senhora da Conceicao

    Porto Alegre, Rio Grande do Sul, Brazil

  • TBTC Site 36 TB and Chest Service of Hong Kong, China

    Hong Kong, China

  • TBTC Site 67/ ACTG Site 31730 GHESKIO centers IMIS

    Port-au-Prince, Ouest, Haiti

  • TBTC Site 45/ ACTG Site 30022: Les Centres Gheskio (INLR)

    Port-au-Prince, Ouest, Haiti

  • TBTC Site 43/ ACTG Site 31441 BJ Medical College

    Pune, Maharashtra, India

  • TBTC Site 44/ ACTG Site 11701 CART CRS, YRGCARE Medical Centre VHS

    Chennai, Tamil Nadu, India

  • TBTC Site 03/ ACTG Site 12601 Moi University Clinical Research Site

    Eldoret, Kenya

  • TBTC Site 02/ ACTG 12501 Kenya Medical Research Institute/Walter Reed Project Clinical Research Center (KEMRI/WRP) CRS

    Kericho, Kericho County, Kenya

  • TBTC Site 39/ ACTG Site 31460 Kisumu CRS

    Kisumu, Nyanza Province, Kenya

  • TBTC Site 04/ ACTG Site 30301 Blantyre CRS (or College of Medicine - Johns Hopkins Research Project, COM-JHP)

    Blantyre, Malawi

  • TBTC Site 05/ ACTG Site 12001 UNC Project Tidziwe Centre

    Lilongwe, Malawi

  • TBTC Site 90/ ACTG Site 11301 Asociacion Civil Impacta Salud y Educacion

    Lima, Peru

  • TBTC Site 93/ ACTG Site 11302 CRS San Miguel

    Lima, Peru

  • TBTC Site 07/ ACTG Site 11101 Wits Helen Joseph CRS

    Johannesburg, South Africa

  • TBTC Site 10/ ACTG Site 31718 TASK Applied Science

    Bellville, Cape Town, South Africa

  • TBTC Site 09/ ACTG Site 31792 University of Cape Town Lung Institute (Pty) Ltd

    Mowbray, Cape Town, South Africa

  • TBTC Site 34 Wits Health Consortium Perinatal HIV Research Unit (PHRU)

    Soweto, Gauteng, South Africa

  • TBTC Site 49/ ACTG Site 12301 Soweto ACTG CRS

    Soweto, Johannesburg, South Africa

  • TBTC Site 06/ ACTG Site 11201 Durban International Clinical Research Site

    Durban, KwaZulu-Natal, South Africa

  • TBTC Site 01/ACTG Site 8950 FAM CRU

    Parow Valley, Western Cape, South Africa

  • TBTC Site 08/ ACTG Site 31793 South African Tuberculosis Vaccine Initiative (SATVI)

    Cape Town, Western Province, South Africa

  • TBTC Site 42/ ACTG Site 31802 The Thai Red Cross AIDS Research Centre

    Pathumwan, Bangkok, Thailand

  • TBTC Site 69/ ACTG Site 31784 Thai-CTIU, CMU HIV Treatment CRS

    Muang Chiang Mai, Chiang Mai, Thailand

  • TBTC Site 11/ ACTG Site 12401 Joint Clinical Research Centre, Kampala Clinical Research Site

    Kampala, Uganda

  • TBTC Site 30 Uganda-Case Western Reserve Research Collaboration

    Kampala, Uganda

  • TBTC Site 37 Vietnam NTP/UCSF Research Collaboration

    Hanoi, Vietnam

  • TBTC Site 41/ ACTG Site 30313 Parirenyatwa Clinical Research Site

    Harare, Zimbabwe

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.